Incidence of Sleep Apnea Syndrome (SAS) in Patients With Bronchial Carcinoma
试验速览
- 阶段
- 不适用
- 入组人数
- 100
- 试验地点
- 3
- 主要终点
- percent of sleep apnea in patients with bronchial carcinoma
研究概览
简要总结
In this study it will be analyzed how often the sleep apnea syndrome can be observed in patients with newly diagnosed lung cancer with the help of ApneaLink device by ResMed.
详细描述
Determination of the SAS- frequence in patients with bronchial carcinoma. The patients will be screened at home for 1 night with the ApneaLink device by ResMed. The apneaLink device is a standard screening tool for sleep apnea in clinical practice.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Screening
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with reasonable suspicion of bronchial carcinoma or histologically proven bronchial carcinoma, which has not been medicated until the study entry and
- •Patients with sleep apnea who had recently been diagnosed with bronchial carcinoma.
排除标准
- •Pregnancy
- •other already known malignancies or tumors
- •Patients with non-invasive artificial respiration due to a chronic respiratory insufficiencies
研究组 & 干预措施
sleep apnea screening with ApneaLinkTM
This is the only group in the present study. Patients with bronchial carcinoma (or reasonable suspicion) perform sleep screening with ApneaLinkTM at home or during the hospitalization.
干预措施: sleep apnea screening with ApneaLinkTM (Device)
结局指标
主要结局
percent of sleep apnea in patients with bronchial carcinoma
时间窗: two days
The percent of sleep apnea in a cohort of patients with bronchial carcinoma will be evaluated. The duration of the study participation is two days.
次要结局
未报告次要终点